Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

OptimizeRx (OPRX) Gains from Sales and Divestitures: 2023-2024

Historic Gains from Sales and Divestitures for OptimizeRx (OPRX) over the last 2 years, with Q4 2024 value amounting to $295018.0.

  • OptimizeRx's Gains from Sales and Divestitures rose 10796.57% to $295018.0 in Q4 2024 from the same period last year, while for Dec 2024 it was $295018.0, marking a year-over-year increase of 10796.57%. This contributed to the annual value of $295018.0 for FY2024, which is 10796.57% up from last year.
  • OptimizeRx's Gains from Sales and Divestitures amounted to $295018.0 in Q4 2024, which was up 10796.57% from $141859.0 recorded in Q4 2023.
  • OptimizeRx's 5-year Gains from Sales and Divestitures high stood at $295018.0 for Q4 2024, and its period low was $141859.0 during Q4 2023.